ARCHIVES

In Brief: Pursell Most Likely To Replace Conte, Foriend Of Cancer Program; DeVita Names Associate

This article is from The Cancer Letter archive.

Vol. 17 No. 07 | February 15, 1991

Download PDF Visit The Full Archive

Related Articles

Give New Investigators “Special Consideration,” Advisors Tell NCI

June 28, 2002

Also NSABP’s STAR Trial Finds Raloxifene Equivalent To Tamoxifen For Breast Cancer Risk Reduction.

April 21, 2006

IOM Says “Immediate Steps” Needed To Avert “Crisis” In Cancer Centers Program Funding

April 28, 1989

FDA Approves Herceptin For HER2+ Metastatic Stomach Cancers

October 22, 2010

One Flexible Sigmoidoscopy Can Reduce Risk by 31 Percent

September 30, 2011

Former NCI Lab Deputy Charged With Two Criminal Counts

January 17, 1992